胃泌素受体颉抗剂对大肠癌肝转移的疗效观察

目的:观察胃泌素拮抗剂对大肠癌肝转移患者的治疗效果。方法:对照组38例常规化疗;治疗组46例常规化疗同时服用胃泌素受体拮抗剂丙谷胺1200mg/d。两组病人每月定期随访1次。结果:对照组患者1年内肝脏转移癌增加(8.1±2.2)cm,死亡率55.3％(21/38);治疗组患者肝脏转移癌1年内增加(3.5±1.2)cm,死亡率21.7％(10/46)均明显低于对照组(P<0.01)。结论:用胃泌素受体拮抗剂对大肠癌肝转移患者进行治疗,可以延缓肿瘤生长,延长患者生存时间,降低患者死亡率。

Observation of Curative Effect of Gastrin Receptor Antagonist on Metastatic Liver Tumors from the Large Intestine Carcinomas

Objective　To observe curative effect of the gastrin receptor antagonist on a metastatic liver concer in the patients with large intestine carcinomas. Methods　Of the 84 patients in whom the large intestine carcinomas had metastasized to the livers, 46 in the therapeutic group were treated by both the conventional chemotherapy and the gastrin receptor antagonist, gastridine (1200 mg per day), and 38 in the control group only received the conventional chemotherapy. A follow-up per month was performed in the patients of both the groups. Results　The diameter of the metastatic liver tumors increased by (3.5±1.2)cm and mortality was 21.9%(10/46) a year after the treatment in the therapeutic group, but the former increased by (8.1±2.2)cm, the latter was 55.3%(21/38) in the control group. Differences between the parameters of both the groups were statistically significant (P<0.01). Conclusions　The metastatic liver tumors growth could be retarded, the survival time proloned and the mortality decreased by the treatment with the gastrin receptor antagonist in the patients with large inestine carcinomashaving metastasized to the livers.